Japanese journal of ophthalmology · 2026
Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamaguchi Chiaki, Himori Noriko, Kiyota Naoki, Misu Tatsuro, Kaneko Kimihiko, Takagi Airi, Suzuki Kotaro, Matsumoto Yuki, Ninomiya Takahiro, Tsuda Satoru, Aoki Masashi, Nakazawa Toru
Аннотация
PURPOSE: To identify risk factors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) during the onset event.
STUDY DESIGN: Retrospective cohort study.
METHODS: We included 44 eyes of 44 Japanese patients with MOG-ON (median age 40.0 years [interquartile range 23.5-54.0]; male to female ratio 16:28) who visited Tohoku University Hospital between August 2013 and December 2024. We compared patient background characteristics; ophthalmic findings, including optical coherence tomography parameters; laboratory findings, including hematological, biochemical, and immunological parameters; anti-MOG antibody titers; and contrast-enhanced orbital MRI findings at baseline in relapse and non-relapse groups. Relapse risk was evaluated using a Kaplan-Meier survival analysis and a Cox proportional hazards regression.
RESULTS: Nine of 44 (20.5%) patients relapsed during follow-up. The Kaplan-Meier analysis showed lower relapse-free survival in patients without eye-movement pain, those with a lower serum IgG level, and those with a thinner macular retinal nerve fiber layer (mRNFL; log-rank P=0.013, 0.049, and 0.040, respectively). In the age- and sex-adjusted Cox proportional hazards analysis, relapse risk was significantly associated with absence of eye-movement pain (hazard ratio [HR] 5.58, 95% confidence interval [CI] 1.35-23.04; P=0.018), a lower serum IgG level (HR 0.55, 95% CI 0.30-1.00; P=0.048), and a higher anti-MOG antibody titer (HR 1.98, 95% CI 1.05-3.71; P=0.034).
CONCLUSION: Baseline absence of eye-movement pain, lower serum IgG level, and higher anti-MOG antibody titer were associated with relapse risk in patients with MOG-ON. A thinner mRNFL may represent a potential marker of relapse-related outcomes.
STUDY DESIGN: Retrospective cohort study.
METHODS: We included 44 eyes of 44 Japanese patients with MOG-ON (median age 40.0 years [interquartile range 23.5-54.0]; male to female ratio 16:28) who visited Tohoku University Hospital between August 2013 and December 2024. We compared patient background characteristics; ophthalmic findings, including optical coherence tomography parameters; laboratory findings, including hematological, biochemical, and immunological parameters; anti-MOG antibody titers; and contrast-enhanced orbital MRI findings at baseline in relapse and non-relapse groups. Relapse risk was evaluated using a Kaplan-Meier survival analysis and a Cox proportional hazards regression.
RESULTS: Nine of 44 (20.5%) patients relapsed during follow-up. The Kaplan-Meier analysis showed lower relapse-free survival in patients without eye-movement pain, those with a lower serum IgG level, and those with a thinner macular retinal nerve fiber layer (mRNFL; log-rank P=0.013, 0.049, and 0.040, respectively). In the age- and sex-adjusted Cox proportional hazards analysis, relapse risk was significantly associated with absence of eye-movement pain (hazard ratio [HR] 5.58, 95% confidence interval [CI] 1.35-23.04; P=0.018), a lower serum IgG level (HR 0.55, 95% CI 0.30-1.00; P=0.048), and a higher anti-MOG antibody titer (HR 1.98, 95% CI 1.05-3.71; P=0.034).
CONCLUSION: Baseline absence of eye-movement pain, lower serum IgG level, and higher anti-MOG antibody titer were associated with relapse risk in patients with MOG-ON. A thinner mRNFL may represent a potential marker of relapse-related outcomes.